Pernix Therapeutics, Inc. Reports Third Quarter 2013 Financial Results

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date period ended September 30, 2013.

During the quarter, the Company completed its previously announced agreement to sell certain generic assets owned by its subsidiary, Cypress Pharmaceuticals, to Breckenridge Pharmaceutical, Inc. for $29.7 million. Under the terms of the agreement, Breckenridge paid Pernix approximately $20 million at closing and $9.7 million which is to be paid in two equal installments over the next two years on the anniversary date of the closing.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC